DI LORENZO, GIORGIA
 Distribuzione geografica
Continente #
EU - Europa 179
NA - Nord America 65
AS - Asia 62
SA - Sud America 12
OC - Oceania 1
Totale 319
Nazione #
DE - Germania 117
US - Stati Uniti d'America 64
CN - Cina 18
IT - Italia 18
IN - India 14
SG - Singapore 14
SE - Svezia 13
BR - Brasile 11
NL - Olanda 8
GB - Regno Unito 6
HK - Hong Kong 6
RU - Federazione Russa 6
FR - Francia 4
IE - Irlanda 4
FI - Finlandia 2
ID - Indonesia 2
IQ - Iraq 2
AU - Australia 1
BD - Bangladesh 1
BO - Bolivia 1
BS - Bahamas 1
IL - Israele 1
JP - Giappone 1
KR - Corea 1
LT - Lituania 1
PH - Filippine 1
TR - Turchia 1
Totale 319
Città #
Frankfurt am Main 109
Chandler 21
Milan 13
Singapore 12
Council Bluffs 6
Princeton 6
Santa Clara 5
Dublin 4
Hong Kong 4
Southend 4
Berlin 3
Phoenix 3
Ashburn 2
Bengaluru 2
Helsinki 2
Hyderabad 2
Jakarta 2
Kent 2
Munich 2
New York 2
Rho 2
Amsterdam 1
Aparecida de Goiânia 1
Armazém 1
Baghdad 1
Basra 1
Beijing 1
Bühl 1
Cambridge 1
Campos dos Goytacazes 1
Cascina 1
Columbus 1
Contagem 1
Des Moines 1
Eitensheim 1
Fairfield 1
Fuzhou 1
Haifa 1
Istanbul 1
Itatiba 1
Jinhua 1
Kendal 1
La Paz 1
Las Vegas 1
Medford 1
Monmouth Junction 1
Nanjing 1
Nassau 1
Pasadena 1
Ribeirão Preto 1
Rio de Janeiro 1
Seattle 1
Seoul 1
Shenzhen 1
Sydney 1
São Sebastião do Paraíso 1
Tokyo 1
Ubatuba 1
Vapi 1
Vitória da Conquista 1
Wilmington 1
Yubileyny 1
Totale 249
Nome #
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 122
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 105
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 87
Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: A retrospective, multi-center study 16
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis 1
The epidermal growth factor receptors as biological targets in penile cancer 1
How can we improve prognostic models in renal cell carcinoma? 1
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate 1
Peg-filgrastim and cabazitaxel in prostate cancer patients 1
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 1
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection 1
Liquid biopsy in bladder cancer: State of the art and future perspectives 1
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy 1
How to carry out retrospective studies in metastatic renal cell cancer: Two caveats that should be avoided 1
Soluble interleukin-6 receptor to interleukin-6 (sIL-6r/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 1
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer 1
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer 1
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms 1
Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients (Cancer Chemotherapy and Pharmacology (2011) DOI: 10.1007/s00280-011-1594-z) 1
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients 1
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study 1
Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure? 1
Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers 1
Paclitaxel in pretreated metastatic penile cancer: Final results of a phase 2 study 1
Totale 350
Categoria #
all - tutte 1.039
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.039


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 1 4 1 0
2021/202248 1 3 1 2 11 2 2 3 7 1 2 13
2022/202360 7 11 7 6 7 8 0 4 4 0 6 0
2023/2024102 0 2 4 2 8 5 16 15 6 13 17 14
2024/2025134 16 11 11 20 9 24 14 13 4 12 0 0
Totale 350